Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and lenalidomide

erlotinib hydrochloride has been researched along with lenalidomide in 3 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(lenalidomide)		Trials
(lenalidomide)		Recent Studies (post-2010) (lenalidomide)
4,3537863,0333,5327252,850

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)lenalidomide (IC50)
Bromodomain-containing protein 4Homo sapiens (human)5.19
DNA damage-binding protein 1Homo sapiens (human)1.5953
Protein cereblonHomo sapiens (human)1.6572

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cooney, MM; Remick, SC; Vogelzang, NJ1
Curtiss, FR1
Hu, YQ; Meyer, S; Moyo, H; Tomlinson, C; Waterhouse, C1

Reviews

1 review(s) available for erlotinib hydrochloride and lenalidomide

ArticleYear
Promising systemic therapy for renal cell carcinoma.
    Current treatment options in oncology, 2005, Volume: 6, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide

2005

Other Studies

2 other study(ies) available for erlotinib hydrochloride and lenalidomide

ArticleYear
Pharmacy benefit spending on oral chemotherapy drugs.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States

2006
How patent law reform can improve affordability and accessibility of medicines in South Africa: Four medicine case studies.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2019, May-31, Volume: 109, Issue:6

    Topics: Antineoplastic Agents; Antiviral Agents; Costs and Cost Analysis; Drug Costs; Drug Industry; Erlotinib Hydrochloride; Guanine; Health Services Accessibility; Humans; Immunologic Factors; Lenalidomide; Patents as Topic; Pharmaceutical Preparations; Sorafenib; South Africa

2019